Treatment of Bowen's disease and erythroplasia of Queyrat

被引:34
作者
Arlette, JP
机构
关键词
Bowen's disease; squamous cell carcinoma in situ; erthyroplasia of Queyrat; imiquimod;
D O I
10.1046/j.0366-077X.2003.05635.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Bowen's disease of the skin may have differing clinical presentations depending on the skin surface on which it presents, but has the same histologic features of squamous cell carcinoma ill situ wherever it occurs. The etiologic factors include ultraviolet light and human papillomavirus infection. The choice of therapy requires a consideration for retention of form, function and cosmosis while offering a high cure rate. The immunodualtory agent imiquimod has been shown to be an effective treatment on a variety of skin surfaces.
引用
收藏
页码:43 / 47
页数:5
相关论文
共 46 条
[31]  
Pehoushek J, 2001, ARCH DERMATOL, V137, P14
[32]  
PETERKA ES, 1961, ARCH DERMATOL, V83, P76
[33]   High incidence of lichen sclerosus in patients with squamous cell carcinoma of the penis [J].
Powell, J ;
Robson, A ;
Cranston, D ;
Wojnarowska, F ;
Turner, R .
BRITISH JOURNAL OF DERMATOLOGY, 2001, 145 (01) :85-89
[34]   BOWENS-DISEASE (SQUAMOUS-CELL CARCINOMA IN-SITU) IN KAUAI, HAWAII - A POPULATION-BASED INCIDENCE REPORT [J].
REIZNER, GT ;
CHUANG, TY ;
ELPERN, DJ ;
STONE, JL ;
FARMER, ER .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 31 (04) :596-600
[35]  
SANCA MR, 1999, J AM ACAD DERMATOL, V41, P911
[36]   Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream [J].
Schroeder, TL ;
Sengelmann, RD .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (04) :545-548
[37]   Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy [J].
Smith, KJ ;
Germain, M ;
Skelton, H .
DERMATOLOGIC SURGERY, 2001, 27 (06) :561-564
[38]   Bowen's disease (Squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a COX inhibitor, sulindac: Potential applications for this combination of immunotherapy [J].
Smith, KJ ;
Germain, M ;
Skelton, H .
DERMATOLOGIC SURGERY, 2001, 27 (02) :143-146
[39]  
Soria JC, 1998, B CANCER, V85, P773
[40]  
Stables GI, 1999, BRIT J DERMATOL, V140, P514